e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Basic research on lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Histone deacetylase inhibitor panobinostat reduces hypoxia-related cisplatin resistance in NSCLC cells by HDAC-mediated Hifalpha destabilization
C. Fischer, K. Leithner, C. Wohlkoenig, E. Stacher, A. Olschewski, H. Olschewski, A. Hrzenjak (Graz, Austria)
Source:
Annual Congress 2013 –Basic research on lung cancer
Session:
Basic research on lung cancer
Session type:
Poster Discussion
Number:
3105
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Fischer, K. Leithner, C. Wohlkoenig, E. Stacher, A. Olschewski, H. Olschewski, A. Hrzenjak (Graz, Austria). Histone deacetylase inhibitor panobinostat reduces hypoxia-related cisplatin resistance in NSCLC cells by HDAC-mediated Hifalpha destabilization. Eur Respir J 2013; 42: Suppl. 57, 3105
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions
Related content which might interest you:
Comparison of anticancer effects of a novel histone deacetylase (HDAC) inhibitor CG200745 and SAHA in non-small lung cancer cells
Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer
Year: 2019
SMYD3 links lysine methylation of MAP3K2 to ras-driven lung cancer
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Possible role of nuclear receptor nr4a1 in hypoxia-induced cisplatin resistance
Source: Annual Congress 2013 –Basic research on lung cancer
Year: 2013
Histone demethylation and acetylation are involved in the epigenetic regulation of epithelial-mesenchymal transition (EMT)
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
RBM5 overexpression reverses acquired resistance to gefitinib in PC9/AB2 NSCLC cells
Source: International Congress 2016 – Late-breaking translational research in lung cancer
Year: 2016
Simvastatin overcomes gefitinib resistance in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor via Akt/b-catenin signaling dependent down-regulation of survivin
Source: Annual Congress 2013 –Basic research on lung cancer
Year: 2013
Glucocorticoid reduces pemetrexed sensitivity by mediating senescence-associated secretory phenotype in Bcl-2 dependent manner in non-small-cell lung cancer
Source: Annual Congress 2013 –Basic research on lung cancer
Year: 2013
Histone deacetylase inhibition significantly augments human mesothelioma cellular response to chemotherapeutic agents
Source: Eur Respir J 2001; 18: Suppl. 33, 396s
Year: 2001
Prx1 modulates the chemosensitivity of lung cancer to docetaxel through suppression of FOXO1-induced apoptosis
Source: Annual Congress 2012 - New insights in the pathology of lung cancer
Year: 2012
The role of HIF-1 pathway in non-small-cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer
Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours
Year: 2015
Dihydroartemisinin combined with cisplatinum induced apoptosis and related mechanism research in human lung adenocarcinoma H1299 cells
Source: International Congress 2016 – Lung cancer and immune cells: friends or foes?
Year: 2016
Shikonin-induced necroptosis is enhanced by the inhibition of autophagy in non-small cell lung cancer cells
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
Cox-2 inhibitors in the treatment of small cell lung cancer patients
Source: International Congress 2015 – Advances in the therapy of lung cancer
Year: 2015
Investigate which PKC isoform play an important role in human lung cancer cells against TRAIL-induced apoptosis
Source: Annual Congress 2013 –Basic research on lung cancer
Year: 2013
Re-education of tumor-associated macrophages by modulating histone deacetylases in lung cancer
Source: ERS Lung Science Conference 2017
Year: 2017
LSC - 2017 - Re-education of tumor-associated macrophages by modulating histone deacetylases in lung cancer
Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells
Year: 2017
Translocation of beta-catenin into cytoplasm during TGFbeta-induced EMT is negatively regulated by phosphorylation of the PTEN C-terminus in lung cancers
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013
TRAP1 downregulation could overcome gefitinib resistance in NSCLC via EMT reversal
Source: International Congress 2018 – Lung cancer: novel molecular markers and mechanisms
Year: 2018
Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study
Source: Eur Respir J 2011; 37: 129-135
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept